Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$804.61 USD

804.61
2,092,822

-1.53 (-0.19%)

Updated Nov 5, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow

by Kinjel Shah

FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3

Lilly's Pancreatic Cancer Candidate Fails in Phase III Study

by Zacks Equity Research

Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.

Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This is Why Eli Lilly (LLY) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Lilly Gets FDA Approval for New Oral Tablets for Migraine

by Zacks Equity Research

Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.

Kinjel Shah headshot

Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

by Kinjel Shah

FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

Gilead-Galapagos Report Efficacy & Safety Results on RA Drug

by Zacks Equity Research

Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.

Kinjel Shah headshot

3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates

by Kinjel Shah

Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

by Zacks Equity Research

J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.

Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

by Zacks Equity Research

Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.

Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan

by Zacks Equity Research

Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.

Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

by Zacks Equity Research

Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.

Novo Nordisk Focuses on Pipeline Development Amid Competition

by Zacks Equity Research

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.

The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly

Why Lilly (LLY) Could Beat Earnings Estimates Again

by Zacks Equity Research

Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Novartis Reports Additional Data on Spondylitis Drug Cosentyx

by Zacks Equity Research

Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.

Here's Why You Should Add Thermo Fisher to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

Mark Vickery headshot

Top Research Reports for Bank of America, Home Depot & Philip Morris

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), The Home Depot (HD) and Philip Morris International (PM).

Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study

by Zacks Equity Research

Agios' (AGIO) Tibsovo improves progression free survival and reduces risk of disease progression or death in a phase III study in previously treated patients with IDH1 mutant cholangiocarcinoma.

Novartis (NVS) Announces Data on Asthma Drugs & Kisqali

by Zacks Equity Research

Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.

Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study

by Zacks Equity Research

Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.

IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA

by Zacks Equity Research

IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.

Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance

by Zacks Equity Research

Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.